Regenxbio is ranked Strong Buy due to low EV, strong partnerships, royalty income, bullish trends, and buyout potential.

Analysts at Chardan Capital reduced their FY2025 earnings estimates for shares of REGENXBIO in a research report issued to ...

Charles Schwab Investment Management Inc. reduced its stake in REGENXBIO Inc. (NASDAQ:RGNX – Free Report) by 16.3% in the 4th ...

Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug ...

Rocket Pharmaceuticals, Inc.’s RCKT share price has dipped by 11.30%, which has investors questioning if this is right time to buy.

Several companies will head to the FDA seeking approval of new Duchenne muscular dystrophy treatments next year but the death ...

Amid readouts from the Muscular Dystrophy Association’s annual meeting, the Clinical Trials Arena evaluates five DMD trials ...

WVE-N531, an oligonucleotide, elicited significant functional benefit and reversal of muscle damage in the Phase II ...

Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Immatics ( IMTX – Research Report) today and set a price target of $13.00. The company’s shares closed yesterday at $4.71.

In a report released today, Alec Stranahan from Bank of America Securities reiterated a Sell rating on Bioxcel Therapeutics (BTAI – Research ...

Successful End-of-Phase 2 Meeting with FDA Results in Alignment on Phase 3 Plans for CLS-AX in Wet AMD - - Asia-Pacific Partner’s New Drug Application for ARCATUS® (XIPERE®) for Uveitic Macular Edema ...